Walleye Capital LLC Makes New Investment in Inari Medical, Inc. (NASDAQ:NARI)

Walleye Capital LLC acquired a new position in Inari Medical, Inc. (NASDAQ:NARIGet Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,062 shares of the company’s stock, valued at approximately $459,000.

Other large investors have also recently bought and sold shares of the company. EFG Asset Management North America Corp. purchased a new position in Inari Medical in the fourth quarter worth $1,671,000. Wedbush Securities Inc. raised its position in Inari Medical by 4.3% in the first quarter. Wedbush Securities Inc. now owns 6,222 shares of the company’s stock worth $564,000 after acquiring an additional 257 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Inari Medical by 16.9% in the first quarter. Envestnet Asset Management Inc. now owns 21,116 shares of the company’s stock worth $1,914,000 after acquiring an additional 3,046 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Inari Medical by 13.2% in the first quarter. Brown Advisory Inc. now owns 694,228 shares of the company’s stock valued at $62,927,000 after buying an additional 81,166 shares in the last quarter. Finally, Lisanti Capital Growth LLC increased its position in shares of Inari Medical by 20.7% in the first quarter. Lisanti Capital Growth LLC now owns 98,325 shares of the company’s stock valued at $8,912,000 after buying an additional 16,865 shares in the last quarter. Hedge funds and other institutional investors own 84.11% of the company’s stock.

Insiders Place Their Bets

In other Inari Medical news, COO Andrew Hykes sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $70.31, for a total value of $351,550.00. Following the sale, the chief operating officer now directly owns 140,991 shares of the company’s stock, valued at approximately $9,913,077.21. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Donald B. Milder sold 7,000 shares of the stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $80.25, for a total value of $561,750.00. Following the completion of the sale, the director now owns 3,199,614 shares of the company’s stock, valued at $256,769,023.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Andrew Hykes sold 5,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $70.31, for a total transaction of $351,550.00. Following the completion of the sale, the chief operating officer now directly owns 140,991 shares of the company’s stock, valued at approximately $9,913,077.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 155,204 shares of company stock valued at $11,677,586. Insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NARI shares. Canaccord Genuity Group raised their price target on Inari Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, September 16th. Truist Financial started coverage on Inari Medical in a research report on Monday, September 12th. They issued a “hold” rating and a $87.00 price target for the company. Piper Sandler started coverage on Inari Medical in a research report on Tuesday, June 21st. They issued an “overweight” rating and a $100.00 price target for the company. Canaccord Genuity Group raised their price target on Inari Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, September 16th. Finally, BTIG Research dropped their price target on Inari Medical from $130.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, June 24th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.71.

Inari Medical Trading Down 2.9 %

Shares of NASDAQ:NARI opened at $65.58 on Friday. The stock’s 50-day moving average price is $75.17 and its two-hundred day moving average price is $74.89. Inari Medical, Inc. has a 12-month low of $50.50 and a 12-month high of $100.00. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -226.14 and a beta of 1.49.

Inari Medical (NASDAQ:NARIGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. Inari Medical had a negative return on equity of 4.60% and a negative net margin of 4.47%. The firm had revenue of $92.74 million for the quarter, compared to analyst estimates of $88.04 million. As a group, research analysts forecast that Inari Medical, Inc. will post -0.67 earnings per share for the current fiscal year.

Inari Medical Profile

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Articles

Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARIGet Rating).

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.